A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab

References

• http://www.fda.gov/cder/foi/label/2003/etanimm060503LB.pdf (accessed 15 May 2004)
   Google Scholar
• http://www.fda.gov/cder/foi/label/2002/inflcen022702LB. pdf (accessed 15 May 2004)
   Google Scholar
• http://www.fda.gov/cder/foi/label/2002/adalabb123102LB. pdf (accessed 15 May 2004)
   Google Scholar
• http://www.rheumatology.org/publications/hotline/0901tnf. asp?aud=mem (accessed 15 May 2004)
   Google Scholar
• Briefing document, FDA Arthritis Advisory Committee meeting; Bethesda, MD; 4 March 2003.
   Google Scholar
• http://www.medscape.com/viewprogram/2769 (accessed 15 May 2004).
   Google Scholar
• Cush JJ, Safety of new biologic therapies in rheumatoid arthritis. Bull Rheum Dis (2003) 52: 8. (http://www. arthritis.org/research/Bulletin/Vol52No8/Introduction.asp)
   Google Scholar
• Aithal GP, Mansfield JC, Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther (2001) 15: 1101–8.
   PubMed Web of Science ®Google Scholar
• Ekstrom K, Hjalgrim H, Brandt L et al, Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum (2003) 48: 963–70.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Berlin J, van Voorhees A, Margolis DJ, Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol (2003) 139: 1425–9.
   PubMed Web of Science ®Google Scholar
• Brown SL, Greene MH, Gershon SK et al, Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum (2002) 46: 3151–8.
   PubMed Web of Science ®Google Scholar
• http://www.upmccancercenters.com/news/reuters/reuters. cfm?article=1305 (accessed 15 May 2004)
   Google Scholar
• Wasko MC, Comorbid conditions in patients with rheumatic diseases: an update. Curr Opin Rheumatol (2004) 16: 109–13.
   PubMed Web of Science ®Google Scholar
• Mikuls TR, Weaver AL, Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Curr Rheumatol Rep (2003) 5: 270–7.
   PubMedGoogle Scholar
• Aithal GP, Mansfield JC, Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther (2001) 15: 1101–8.
   PubMed Web of Science ®Google Scholar
• Roddy E, Courtney PA, Morris A, Non-Hodgkin’s lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology (Oxford) (2002) 41: 1194–5.
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Giannouli S, Tzioufas AG, Voulgarelis M, Lymphoma development in a patient receiving anti-TNF therapy. Haematologica (2003) 88: ECR25.
   Google Scholar
• Kosary CL, Ries LAG, Miller BA et al, 1973–1992: Tables and Graphs. National Cancer Institute: Bethesda, MD. NIH Pub. No. 96–2789 1995.
   Google Scholar
• Smith K, Skelton H, Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha IgG1-Fc fusion complex therapy. J Am Acad Dermatol (2001) 45: 953–6.
   PubMed Web of Science ®Google Scholar
• Burge D, Etanercept and squamous cell carcinoma. J Am Acad Dermatol (2003) 49: 358–9.
   PubMed Web of Science ®Google Scholar
• Bakland G, Nossent H, Acute myelogenous leukaemia following etanercept therapy. Rheumatology (Oxford) (2003) 42: 900–1.
   PubMed Web of Science ®Google Scholar
• Alcain G, Andrade RJ, Queipo de Llano MP et al, Acute leukemia after infliximab therapy. Am J Gastroenterol (2003) 98: 2577.
   Google Scholar
• Esser AC, Abril A, Fayne S, Doyle JA, Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol (2004) 50 (5 Suppl): S75–7.
   Google Scholar
• Elwood RL, Pelszynski MM, Corman LI, Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulat- ing therapy with etanercept. Pediatr Infect Dis J (2003) 22: 286–8.
   Google Scholar
• Caramaschi P, Biasi D, Carletto A, Bambara LM, Orbital myositis in a rheumatoid arthritis patient during etanercept treatment. Clin Exp Rheumatol (2003) 21: 136–7.
   Web of Science ®Google Scholar
• Smith D, Letendre S, Viral pneumonia as a serious complication of etanercept therapy. Ann Intern Med (2002) 136: 174.
   PubMedGoogle Scholar
• Lee JH, Slifman NR, Gershon SK et al, Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum (2002) 46: 2565–70.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Vicent M, Diaz MA, Sevilla J, Madero L, Cerebral toxoplasmosis following etanercept treatment for idiophatic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT). Ann Hematol (2003) 82: 649–53.
   PubMed Web of Science ®Google Scholar
• Gottlieb GS, Lesser CF, Holmes KK, Wald A, Disseminated sporotrichosis associated with treat- ment with immunosuppressants and tumor necrosis factor-alpha antagonists. Clin Infect Dis (2003) 37: 838–40.
   Google Scholar
• Lassoued S, Sire S, Farny M et al, Pulmonary aspergillosis in a patient with rheumatoid arthritis treated by etanercept. Clin Exp Rheumatol (2004) 22: 267–8.
   PubMedGoogle Scholar
• Yim K, Nazeer SH, Kiska D et al, Recurrent Myco- bacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept. Scand J Infect Dis (2004) 36: 150–4.
   PubMed Web of Science ®Google Scholar
• Cohen CD, Horster S, Sander CA, Bogner JR, Kaposi’s sarcoma associated with tumour necrosis factor alpha neutralising therapy. Ann Rheum Dis (2003) 62: 684.
   PubMed Web of Science ®Google Scholar
• Michel M, Duvoux C, Hezode C, Cherqui D, Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still’s disease. J Rheumatol (2003) 30: 1624–5.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Dignass AU, Shingles following inflix- imab infusion. Ann Rheum Dis (2002) 61: 661.
   Google Scholar
• Kinder A, Stephens S, Mortimer N, Sheldon P, Severe herpes zoster after infliximab infusion. Postgrad Med J (2004) 80: 26.
   Google Scholar
• Helbling D, Breitbach TH, Krause M, Disseminated cytomegalovirus infection inCrohn’s disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol (2002) 14: 1393–5.
   PubMed Web of Science ®Google Scholar
• Cursiefen C, Grunke M, Dechant C et al, Multiple bilateral eyelid molluscum contagiosum lesions asso- ciated with TNFalpha-antibody and methotrexate therapy. Am J Ophthalmol (2002) 134: 270–1.
   PubMed Web of Science ®Google Scholar
• Epstein—Barr virus viral load in Crohn’s disease, effect of immunosuppressive therapy. Inflamm Bowel Dis (2004) 10: 85–90.
   Google Scholar
• Albert C, Vandenbos F, Brocq O et al, Legionellosis in patient treated with infliximab. Rev Med Interne (2004) 25: 167–8.
   Google Scholar
• Olivieri I, Padula A, Armignacco L et al, Septic arthritis caused by Moraxella catarrhalis associated with inflix- imab treatment in a patient with undifferentiated spondarthritis. Ann Rheum Dis (2004) 63: 105–6.
   Google Scholar
• Slifman NR, Gershon SK, Lee JH et al, Listeria monocytogenes infection as a complication of treat- ment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum (2003) 48: 319–24.
   PubMed Web of Science ®Google Scholar
• Gluck T, Linde HJ, Scholmerich J et al, Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum (2002) 46: 2255–7.
   Google Scholar
• Ritz MA, Jost R, Severe pneumococcal pneumonia following treatment with infliximab for Crohn’s disease. Inflamm Bowel Dis (2001) 7: 327.
   PubMed Web of Science ®Google Scholar
• Matzkies FG, Manger B, Schmitt-Haendle M et al, Severe septicaemia in a patient with polychondritis and Sweet’s syndrome after initiation of treatment with infliximab. Ann Rheum Dis (2003) 62: 81–2.
   PubMed Web of Science ®Google Scholar
• Gottlieb GS, Lesser CF, Holmes KK, Wald A, Dissemi- nated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists. Clin Infect Dis (2003) 37: 838–40.
   Google Scholar
• Hage CA, Wood KL, Winer-Muram HT et al, Pulmon- ary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest (2003) 124: 2395–7.
   PubMed Web of Science ®Google Scholar
• Tai TL, O’Rourke KP, McWeeney M et al, Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford) (2002) 41: 951–2.
   PubMed Web of Science ®Google Scholar
• De Rosa FG, Shaz D, Campagna AC et al, Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol (2003) 24: 477–82.
   PubMedGoogle Scholar
• True DG, Penmetcha M, Peckham SJ, Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol (2002) 29: 1561–3.
   PubMed Web of Science ®Google Scholar
• Shrestha RK, Stoller JK, Honari G et al, Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel. Respir Care (2004) 49: 606–8.
   PubMedGoogle Scholar
• Lee JH, Slifman NR, Gershon SK et al, Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum (2002) 46: 2565–70.
   PubMed Web of Science ®Google Scholar
• Nakelchik M, Mangino JE, Reactivation of histoplas- mosis after treatment with infliximab. Am J Med (2002) 112: 78.
   PubMed Web of Science ®Google Scholar
• http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2_ 01_cber_safety%20_revision2.pdf (accessed 15 May 2004)
   Google Scholar
• American Thoracic Society, Centers for Disease Control and Prevention, Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med (2000) 161: S221–7.
   Google Scholar
• Wallis RS, Broder MS, Wong JY et al, Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis (2004) 38: 1261–5.
   PubMed Web of Science ®Google Scholar
• Van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM et al, Disseminated tuberculosis, pulmon- ary aspergillosis and cutaneous herpes simplex infec- tion in a patient with infliximab and methotrexate. Intensive Care Med (2003) 29: 2327–9.
   PubMed Web of Science ®Google Scholar
• Parra Ruiz J, Ortego Centeno N, Raya Alvarez E, Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. J Rheumatol (2003) 30: 1657–8.
   PubMedGoogle Scholar
• Wagner TE, Huseby ES, Huseby JS, Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn’s disease after treatment with a tumor necrosis factor-alpha inhibitor. Am J Med (2002) 112: 67–9.
   PubMed Web of Science ®Google Scholar
• Taylor JC, Orkin R, Lanham J, Tuberculosis following therapy with infliximab may be refractory to anti- biotic therapy. Rheumatology (Oxford) (2003) 42: 901–2.
   Google Scholar
• Keane J, Gershon S, Wise RP et al, Tuberculosis associated with infliximab, a tumor necrosis factor- neutralizing agent. N Engl J Med (2001) 345: 1098–104.
   PubMed Web of Science ®Google Scholar
• Uthman I, Kanj N, El-Sayad J, Bizri AR, Miliary tuberculosis after infliximab therapy in Lebanon. Clin Rheumatol (2004) 23: 279–80.
   PubMed Web of Science ®Google Scholar
• Derk CT, DeHoratius RJ, Tuberculous tonsillitis in a patient receiving etanercept treatment. Ann Rheum Dis (2003) 62: 372.
   Google Scholar
• Manadan AM, Block JA, Sequeira W, Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol (2003) 21: 526.
   PubMed Web of Science ®Google Scholar
• Schiff M, van de Putte LBA, Breedveld FC et al, Rates of infection in adalimumab rheumatoid arthritis clinical trials. Annual European Congress of Rheumatology; 21–23 June 2003; Lisbon (abstr).
   Google Scholar
• Machold KP, Smolen JS, Adalimumab — a new TNF-a antibody for treatment of inflammatory joint disease. Expert Opin Biol Ther (2003) 3: 351–60.
   PubMed Web of Science ®Google Scholar
• Lisman KA, Stetson SJ, Koerner MM et al, The role of tumor necrosis factor alpha blockade in the treatment of congestive heart failure. Congest Heart Fail (2002) 8: 275–9.
   PubMedGoogle Scholar
• Kwon HJ, Cote TR, Cuffe MS et al, Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med (2003) 138: 807–11.
   Google Scholar
• Wolfe F, Michaud K, Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med (2004) 116: 305–11.
   PubMed Web of Science ®Google Scholar
• http://216.239.41.104/search?q=cache:s4zuoc3eJ1QJ: www.fda.gov/ohrms/dockets/ac/03/slides/3930S1_06_ Amgen Enbrel.ppt+lymphoma+and+etanercept=en=UTF- 8 (accessed 21 February 2004).
   Google Scholar
• Louis A, Cleland JG, Crabbe S et al, Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. High- lights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail (2001) 3: 381–7.
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Cote TR, Cuffe MS et al, Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med (2003) 138: 807–11.
   Google Scholar
• Weisman MH, What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl (2002) 65: 33–8.
   PubMedGoogle Scholar
• http://www.emea.eu.int/pdfs/human/press/pus/325701en. pdf (21 February 2004).
   Google Scholar
• Nahar IK, Shojania K, Marra CA et al, Infliximab treatment of rheumatoid arthritis and Crohn’s disease. Ann Pharmacother (2003) 37: 1256–65.
   PubMed Web of Science ®Google Scholar
• European Agency for Evaluation of Medicinal Product- sAvailable from URL: http://www.emea.eu.int 1218 (accessed 21 February 2004).
   Google Scholar
• TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology (1999) 53: 457–65.
   Google Scholar
• Mohan N, Edwards ET, Cupps TR et al, Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum (2001) 44: 2862–9.
   PubMed Web of Science ®Google Scholar
• Sicotte NL, Voskuhl RR, Onset of multiple sclerosis associated with anti-TNF therapy. Neurology (2001) 57: 1885–8.
   PubMed Web of Science ®Google Scholar
• Van der Laken CJ, Lems WF, van Soesbergen RM et al, Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al. Arthritis Rheum (2003) 48: 269–70.
   PubMedGoogle Scholar
• Thomas CW Jr, Weinshenker BG, Sandborn WJ, Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis (2004) 10: 28–31.
   Google Scholar
• Foroozan R, Buono LM, Sergott RC, Savino PJ, Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol (2002) 120: 985–7.
   PubMed Web of Science ®Google Scholar
• En Tusscher MP, Jacobs PJ, Busch MJ et al, Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ (2003) 326: 579.
   Google Scholar
• Mejico LJ, Infliximab-associated retrobulbar optic neur- itis. Arch Ophthalmol (2004) 122: 793–4.
   PubMed Web of Science ®Google Scholar
• Strong BY, Erny BC, Herzenberg H, Razzeca KJ, Retrobulbar optic neuritis associated with infliximab in a patient with Crohn’s disease. Ann Intern Med (2004) 140(8): W34.
   PubMedGoogle Scholar
• Cisternas M, Gutierrez M, Jacobelli S, Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyeli- nating nervous system disease during initial treat- ment: comment on the article by Mohan et al. Arthritis Rheum (2002) 46: 3107–8; author reply 3108–9.
   Google Scholar
• Carlson E, Rothfield N, Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum (2003) 48: 1165–6.
   PubMed Web of Science ®Google Scholar
• Cairns AP, Duncan MK, Hinder AE, Taggart AJ, New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis (2002) 61: 1031–2.
   PubMed Web of Science ®Google Scholar
• Brion PH, Mittal-Henkle A, Kalunian KC, Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med (1999) 131: 634.
   PubMed Web of Science ®Google Scholar
• Shakoor N, Michalska M, Harris CA et al, Drug-induced systemic lupus erythematosus associated with etaner- cept therapy. Lancet (2002) 359: 579–80.
   PubMed Web of Science ®Google Scholar
• Bleumink GS, ter Borg EJ, Ramselaar CG, Ch Stricker BH, Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) (2001) 40: 1317–19.
   PubMed Web of Science ®Google Scholar
• Misery L, Perrot JL, Gentil-Perret A et al, Dermatolo- gical complications of etanercept therapy for rheuma- toid arthritis. Br J Dermatol (2002) 146: 334–5.
   PubMed Web of Science ®Google Scholar
• Lepore L, Marchetti F, Facchini S et al, Drug-induced systemic lupus erythematosus associated with etaner- cept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol (2003) 21: 276–7.
   PubMed Web of Science ®Google Scholar
• Swale VJ, Perrett CM, Denton CP et al, Etanercept- induced systemic lupus erythematosus. Clin Exp Dermatol (2003) 28: 604–7.
   PubMed Web of Science ®Google Scholar
• Non-Hodgkin’s lymphoma in a patient with refractory dermatomyositis which had been treated with inflix- imabRheumatology (Oxford) (2002) 41: 1194–5.
   Google Scholar
• Debandt M, Vittecoq O, Descamps V et al, Anti-TNF- alpha-induced systemic lupus syndrome. Clin Rheuma- tol (2003) 22: 56–61.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Sinigaglia L, Varenna M, Arnoldi C, Drug- induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus (2002) 11: 753–5.
   PubMed Web of Science ®Google Scholar
• Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB, A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis (2003) 9: 176–8.
   PubMed Web of Science ®Google Scholar
• Russell E, Zeihen M, Wergin S, Litton T, Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays. Arthritis Rheum (2000) 43: 944.
   PubMed Web of Science ®Google Scholar
• Ferraccioli G, Mecchia F, Di Poi E, Fabris M, Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis (2002) 61: 358–61.
   PubMed Web of Science ®Google Scholar
• Bobbio-Pallavicini F, Alpini C, Caporali R et al, Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther (2004) 6: R264–72.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE et al, Adalimu- mab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 48: 35–45. Erratum: 2003; 48: 855.
   Google Scholar
• Van de Putte LBA, Atkins C, Malaise M et al, Adalimumab (DE27) monotherapy in the treatment of patients with severely active rheumatoid arthritis. Arthritis Rheum (2002) 46(9 suppl): S205 [abstract no. 467].
   Google Scholar
• Keystone E, Kavanaugh AF, Sharp J et al, Adalimumab (DE27), a fully human anti-TNF-alpha monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy. Arthritis Rheum (2002) 46(9 suppl): S205 [abstract no. 468 plus oral proceedings].
   Google Scholar
• Zeltser R, Valle L, Tanck C et al, Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol (2001) 137: 893–9.
   PubMed Web of Science ®Google Scholar
• Werth VP, Levinson AI, Etanercept-induced injection site reactions: mechanistic insights from clinical findings and immunohistochemistry. Arch Dermatol (2001) 137: 953–5.
   PubMed Web of Science ®Google Scholar
• Murphy FT, Enzenauer RJ, Battafarano DF, David-Bajar K, Etanercept-associated injection-site reactions. Arch Dermatol (2000) 136: 556–7.
   PubMed Web of Science ®Google Scholar
• Edwards KR, Mowad CM, Tyler WB, Worsening injection site reactions with continued use of etaner- cept. J Drugs Dermatol (2003) 2: 184–7.
   PubMedGoogle Scholar
• Cheifetz A, Smedley M, Martin S et al, The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol (2003) 98: 1315–24.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Loftus EV Jr, Tremaine WJ et al, The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology (2004) 126: 19–31.
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Shah SA, Lodhavia PJ et al, Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol (2000) 95: 3490–7.
   PubMed Web of Science ®Google Scholar
• Jarrett SJ, Cunnane G, Conaghan PG et al, Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol (2003) 30: 2287–91.
   PubMed Web of Science ®Google Scholar
• Galaria NA, Werth VP, Schumacher HR, Leukocyto- clastic vasculitis due to etanercept. J Rheumatol (2000) 27: 2041–4.
   PubMed Web of Science ®Google Scholar
• McCain ME, Quinet RJ, Davis WE, Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) (2002) 41: 116–17.
   PubMed Web of Science ®Google Scholar
• Misery L, Perrot JL, Gentil-Perret A et al, Dermatolo- gical complications of etanercept therapy for rheuma- toid arthritis. Br J Dermatol (2002) 146: 334–5.
   PubMed Web of Science ®Google Scholar
• Kekow J, Welte T, Kellner U, Pap T, Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept. Arthritis Rheum (2002) 46: 843–4.
   PubMed Web of Science ®Google Scholar
• Mangge H, Gindl S, Kenzian H, Schauenstein K, Atopic dermatitis as a side effect of anti-tumor necrosis factor- alpha therapy. J Rheumatol (2003) 30: 2506–7.
   PubMed Web of Science ®Google Scholar
• Soliotis F, Glover M, Jawad AS, Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis (2002) 61: 850–1.
   Google Scholar
• Skytta E, Pohjankoski H, Savolainen A, Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol (2000) 18: 533–4.
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Shajrawi I, Sarcoid-related uveitis occur- ring during etanercept therapy. Clin Exp Rheumatol (2003) 21: 645–6.
   PubMed Web of Science ®Google Scholar
• McIlwain L, Carter JD, Bin-Sagheer S et al, Hypersen- sitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol (2003) 36: 411–13.
   PubMed Web of Science ®Google Scholar
• Kent PD, Davis JM rd, Davis MD, Matteson EL, Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum (2002) 46: 2257–8.
   PubMed Web of Science ®Google Scholar
• Chan AT, Cleeve V, Daymond TJ, Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J (2002) 78: 47–8.
   PubMed Web of Science ®Google Scholar
• Cutaneous ulceration with methotrexatePrescrire Int (2003) 12: 59–60.
   Google Scholar
• Vanbiervliet G, Anty R, Schneider S et al, Sweet’s syndrome and erythema nodosum associated with Crohn’s disease treated by infliximab. Gastroenterol Clin Biol (2002) 26: 295–7.
   Google Scholar
• Yucel AE, Kart-Koseoglu H, Akova YA et al, Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behcet’s disease. Rheumatology (Oxford) (2004) 43: 394–6.
   PubMed Web of Science ®Google Scholar
• Vergara G, Silvestre JF, Betlloch I et al, Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol (2002) 138: 1258–9.
   Google Scholar
• Verea MM, Del Pozo J, Yebra-Pimentel MT et al, Psoriasiform eruption induced by infliximab. Ann Pharmacother (2004) 38: 54–7.
   PubMed Web of Science ®Google Scholar
• Lobel EZ, Korelitz BI, Warman JI, Red man syndrome and infliximab. J Clin Gastroenterol (2003) 36: 186.
   Google Scholar
• Kiely PD, Johnson DM, Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open- label study. Rheumatology (Oxford) (2002) 41: 631–7.
   PubMed Web of Science ®Google Scholar
• Heart failure on infliximab. Prescrire Int (2002) 11: 86–7.
   Google Scholar
• Wang LC, Medenica MM, Shea CR, Busbey S, Infliximab-induced eczematid-like purpura of Doucas and Kapetenakis. J Am Acad Dermatol (2003) 49: 157–8.
   PubMed Web of Science ®Google Scholar
• Chan JL, Davis-Reed L, Kimball AB, Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol (2004) 3: 315–18.
   PubMedGoogle Scholar
• Wright RC, Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol (2003) 49: 160–1.
   PubMed Web of Science ®Google Scholar
• Katsanos KH, Christodoulou DK, Zioga A, Tsianos EV, Cutaneous nevi pigmentosus during infliximab therapy in a patient with Crohn’s disease: fallacy or coin- cidence? Inflamm Bowel Dis (2003) 9: 279.
   PubMed Web of Science ®Google Scholar
• Cush JJ, Kavanaugh AF, FDA Meeting March 2003: Update on the safety of new drugs for rheumatoid arthritis. Part II: CHF, infection and other safety issues. Hotline. American College of Rheumatology; Atlanta, GA. August 2003.
   Google Scholar
• Kuruvilla J, Leitch HA, Vickars LM et al, Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol (2003) 71: 396–8.
   PubMed Web of Science ®Google Scholar
• Peno-Green L, Lluberas G, Kingsley T, Brantley S, Lung injury linked to etanercept therapy. Chest (2002) 122: 1858–60.
   Google Scholar
• Andres E, Limbach FX, Goichot B, Sibilia J, Silent thyroiditis associated with etanercept in rheumatoid arthritis. Ann Rheum Dis (2002) 61: 565.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Bremont C, Kahan A, Menkes CJ, Transient hyperthyroidism in a patient with rheumatoid arthritis treated by etanercept. Clin Exp Rheumatol (2001) 19: 356–7.
   PubMed Web of Science ®Google Scholar
• Marotte H, Charrin JE, Miossec P, Infliximab-induced aseptic meningitis. Lancet (2001) 358: 1784.
   PubMed Web of Science ®Google Scholar
• Kashyap AS, Kashyap S, Infliximab-induced aseptic meningitis. Lancet (2002) 359: 1252.
   PubMedGoogle Scholar
• Musial J, Undas A, Celinska-Lowenhoff M, Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford) (2003) 42: 1566–8.
   PubMed Web of Science ®Google Scholar
• Menon Y, Cucurull E, Espinoza LR, Pancytopenia in a patient with scleroderma treated with infliximab. Rheumatology (Oxford) (2003) 42: 1273–4.
   Google Scholar
• Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximabRheumatology (Oxford) (2003) 42: 193–4.
   Google Scholar
• Krishnan RS, Hsu S, Serum sickness due to infliximab in a patient with psoriasis. J Drugs Dermatol (2004) 3: 305–8.
   Google Scholar
• O’Connor M, Buchman A, Marshall G, Anaphylaxis- like reaction to infliximab in a patient with Crohn’s disease. Dig Dis Sci (2002) 47: 1323–5.
   PubMed Web of Science ®Google Scholar
• Triantafillidis JK, Cheracakis P, Hereti IA et al, Acute idiopathic pancreatitis complicating active Crohn’s disease: favorable response to infliximab treatment. Am J Gastroenterol (2000) 95: 3334–6.
   Google Scholar
• Menghini VV, Arora AS, Infliximab-associated rever- sible cholestatic liver disease. Mayo Clin Proc (2001) 76: 84–6.
   PubMed Web of Science ®Google Scholar
• Den Broeder AA, Assmann KJ, van Riel PL, Wetzels JF, Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis. Neth J Med (2003) 61: 137–41.
   PubMed Web of Science ®Google Scholar
• Beuthien W, Mellinghoff HU, von Kempis J, Skin reactions to adalimumab. Arthritis Rheum (2004) 50: 1690–2.
   PubMed Web of Science ®Google Scholar